Ischemia Reperfusion Injury Therapeutic and Overview Pipeline Review H2 adds Exclusive Research on “Ischemia Reperfusion Injury – Pipeline Review, H2 2016” reports to its database.

The report provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ischemia Reperfusion Injury and features dormant and discontinued projects.




Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.



– The report provides a snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury

– The report reviews pipeline therapeutics for Ischemia Reperfusion Injury by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Ischemia Reperfusion Injury therapeutics and enlists all their major and minor projects

– The report assesses Ischemia Reperfusion Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Ischemia Reperfusion Injury


Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

– Identify and understand important and diverse types of therapeutics under development for Ischemia Reperfusion Injury

– Identify potential new clients or partners in the target demographic

– Develop strategic initiatives by understanding the focus areas of leading companies

– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

– Devise corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury pipeline depth and focus of Indication therapeutics

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 7

Ischemia Reperfusion Injury Overview 8

Therapeutics Development 9

Pipeline Products for Ischemia Reperfusion Injury – Overview 9

Pipeline Products for Ischemia Reperfusion Injury – Comparative Analysis 10

Ischemia Reperfusion Injury – Therapeutics under Development by Companies 11

Ischemia Reperfusion Injury – Therapeutics under Investigation by Universities/Institutes 13

Ischemia Reperfusion Injury – Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Ischemia Reperfusion Injury – Products under Development by Companies 18

Ischemia Reperfusion Injury – Products under Investigation by Universities/Institutes 20

Ischemia Reperfusion Injury – Companies Involved in Therapeutics Development 22

Amyndas Pharmaceuticals LLC 22

Angion Biomedica Corp. 23

Biomedica Management Corporation 24

Bolder Biotechnology, Inc. 25

Corline Biomedical AB 26

Curatis Pharma GmbH 27

Erimos Pharmaceuticals, LLC 28

Gilead Sciences, Inc. 29

Ischemix, Inc. 30

Kowa Company, Ltd. 31

LG Life Science LTD. 32

Omeros Corporation 33

Opsona Therapeutics Limited 34

Orexo AB 35

Pharming Group N.V. 36

PledPharma AB 37




Get in touch:




Media Contact
Company Name:
Contact Person: Norah Trent
Phone: +1 646 845 9349, +44 208 133 9349
City: New York City
State: NY
Country: United States